Murak-Kozanecka Ewa, Rabe-Jabłońska Jolanta
Ze Specjalistycznego Psychiatrycznego ZOZ Szpital im. J. Babińskiego w Łodzi.
Psychiatr Pol. 2004 May-Jun;38(3):491-505.
The aim of the study was to establish prevalence and type of dermatologic symptoms in patients with mental disorders, treated with psychotropics drugs, and comparison of the frequency and type of dermatologic disorders after typical psychotropics and new psychotropic drugs, and assessment of relationships between diagnosis of mental disorders and type of dermatologic symptoms.
In the study 4041 patients hospitalized and treated with psychotropic drugs in a psychiatric hospital took part. Dermatologic consultation was conducted in 340 patients, but only 98 were in monotherapy. This group was assessed with a next procedure: questionnaire regarding demographic dates, early and family dermatologic disorders, treatment with other than psychotropics--drugs, diet, addictions and analysis of medical documentation (psychiatric and dermatologic diagnosis, actual pharmacotherapy).
8.4% of the subjects had dermatologic symptoms, which were consulted by dermatologists. 1/2 of this group had their first treatment with psychotropics. Dermatologic symptoms appeared more often in patients treated with more than 2 psychotropics than in patients in monotherapy, usually in the first weeks of pharmacotherapy. Nearly 1/3rd of these subjects had allergic disorders. In subjects treated with psychotropics the most frequent dermatologic symptoms (allergic diseases, psoriasis and psoriasislike disorders) were noted after therapy with antipsychotics, next anxiolytics. In 3/4 patients treated with antidepressants had vascular diseases of the skin. In the whole group, dermatologic disorders appeared most frequently after treatment with BZD, phenothiazines and butyrophenones. New psychotropic drugs caused less dermatologic symptoms than typical antipsychotics and antidepressants.
本研究旨在确定使用精神药物治疗的精神障碍患者中皮肤症状的患病率和类型，比较使用传统精神药物和新型精神药物后皮肤疾病的频率和类型，并评估精神障碍诊断与皮肤症状类型之间的关系。
本研究纳入了一家精神病医院中4041名住院并接受精神药物治疗的患者。对340名患者进行了皮肤科会诊，但只有98名患者接受单一疗法。对该组患者进行了以下评估：关于人口统计学数据、早期和家族性皮肤疾病、非精神药物治疗、饮食、成瘾情况的问卷调查，以及对医疗记录（精神科和皮肤科诊断、实际药物治疗）的分析。
8.4%的受试者出现了皮肤科医生会诊的皮肤症状。该组中有一半患者首次接受精神药物治疗。使用两种以上精神药物治疗的患者比单一疗法患者更常出现皮肤症状，通常在药物治疗的最初几周出现。这些受试者中近三分之一患有过敏性疾病。在使用精神药物治疗的受试者中，抗精神病药物治疗后出现的皮肤症状最为常见（过敏性疾病、银屑病和银屑病样疾病），其次是抗焦虑药物。在使用抗抑郁药物治疗的患者中，四分之三出现了皮肤血管疾病。在整个组中，使用苯二氮䓬类药物、吩噻嗪类药物和丁酰苯类药物治疗后皮肤疾病出现得最为频繁。新型精神药物引起的皮肤症状比传统抗精神病药物和抗抑郁药物少。
